Is OptimizeRx Corp. overvalued or undervalued?

As of 4 May 2022, OptimizeRx Corp. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued, particularly given its negative earnings performance reflected in a P/E ratio that is not applicable due to losses. Key ratios include a price-to-book value of 2.33, an EV to EBITDA ratio of 271.52, and a return on equity (ROE) of -6.81%.
In comparison to peers, Innovid Corp. has a P/E ratio of -34.42 and an EV to EBITDA of 169.90, while ReposiTrak, Inc. is valued fairly with a P/E of 54.06 and an EV to EBITDA of 46.60. These comparisons highlight the relative risk associated with OptimizeRx Corp. given its high EV to EBITDA ratio and negative returns on capital employed. Despite a strong year-to-date stock return of 167.08%, which outperformed the S&P 500's 2.44%, the underlying financial metrics suggest that the stock is not justified at its current price level.